Literature DB >> 22454797

A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole.

Hannah E Brown1, Alice W Flaherty, Donald C Goff, Oliver Freudenreich.   

Abstract

Entities:  

Year:  2011        PMID： 22454797      PMCID： PMC3304679          DOI： 10.4088/PCC.11l01188

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  9 in total

1.  The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

Authors:  Shaun Jordan; Vuk Koprivica; Ruoyan Chen; Katsura Tottori; Tetsuro Kikuchi; C Anthony Altar
Journal:  Eur J Pharmacol       Date:  2002-04-26       Impact factor: 4.432

2.  Aripiprazole-induced improvement in tardive dyskinesia.

Authors:  Harpreet S Duggal
Journal:  Can J Psychiatry       Date:  2003-12       Impact factor: 4.356

3.  Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.

Authors:  Marni J Grant; Ross J Baldessarini
Journal:  Ann Pharmacother       Date:  2005-10-11       Impact factor: 3.154

4.  Resolution of Ziprasidone-Related Tardive Dyskinesia With a Switch to Aripiprazole.

Authors:  Ashish Sharma; Sriram Ramaswamy; Vijay K Dewan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

5.  Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics.

Authors:  Lefteris Lykouras; Emmanouil Rizos; Rossetos Gournellis
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-06-22       Impact factor: 5.067

6.  Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy.

Authors:  Ali Caykoylu; Okan Ekinci; Elif Yilmaz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-01-23       Impact factor: 5.067

Review 7.  Tardive dyskinesia.

Authors:  Karla Soares-Weiser; Hubert H Fernandez
Journal:  Semin Neurol       Date:  2007-04       Impact factor: 3.420

8.  The prognosis of tardive dyskinesia.

Authors:  G Gardos; J O Cole
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

9.  Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

Authors:  Kevin D Burris; Thaddeus F Molski; Cen Xu; Elaine Ryan; Katsura Tottori; Tetsuro Kikuchi; Frank D Yocca; Perry B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.